trending Market Intelligence /marketintelligence/en/news-insights/trending/Hm2wwSip9C4edzA0J8f-GQ2 content esgSubNav
In This List

NewLink Genetics reports positive phase 2 results of prostate cancer drug

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


NewLink Genetics reports positive phase 2 results of prostate cancer drug

NewLink Genetics Corp. reported positive results for its phase 2 investigator-initiated study of indoximod in combination with therapeutic cancer vaccine Provenge for patients with metastatic castration-resistant prostate cancer.

The indoximod treatment arm for the study showed a statistically significant improvement in radiographic progression-free survival when compared to placebo and was well tolerated.

Statistically significant improvement in median radiographic progression-free survival was 10.3 months in the treatment arm compared to 4.1 months in the placebo arm. Median overall survival has not yet been reached.